This Article Figures Only Full Text Full Text (PDF) Correction (v37,p339) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, Z. Articles by Lüscher, T. F. Search for Related Content PubMed PubMed Citation Articles by Yang, Z. Articles by Lüscher, T. F.

EXPERIMENTAL STUDY

HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins

Zhihong Yang, MD^* , Toshiyoki Kozai, MD^* , Bernd van de Loo, MD^* , Hema Viswambharan, MSc^* , Mario Lachat, MD, Marko I. Turina, MD, Tadeusz Malinski, PhD and Thomas F. Lüscher, MD, FRCP, FACC^*

^* Department of Cardiovascular Research, Institute of Physiology, University Zürich-Irchel, Zürich, Switzerland
Department of Cardiology, University Hospital, Zürich, Switzerland
Clinic for Cardiovascular Surgery, University Hospital, Zürich, Switzerland
Department of Chemistry, Institut of Biotechnology, Oakland University, Rochester, Michigan, USA

Manuscript received May 10, 1999; revised manuscript received April 20, 2000, accepted June 26, 2000.

Reprint requests and correspondence: Dr. Thomas F. Lüscher, Cardiovascular Center, Cardiology, University Hospital, CH-8091 Zürich/Switzerland

OBJECTIVES

This study examined effects of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor cerivastatin on human saphenous vein (SV), endothelial cells (EC) and smooth muscle cells (SMC).

BACKGROUND

Venous bypass graft failure involves EC dysfunction and SMC proliferation. Substances that improve EC function and inhibit SMC proliferation would be of clinical relevance.

METHODS

Both EC and SMC were isolated from SV. Endothelial nitric oxide synthase (eNOS) expression and nitric oxide (NO) production were analyzed by immunoblotting and porphyrinic microsensor. The SMC proliferation was assayed by ³H-thymidine incorporation. Protein kinases and cell cycle regulators were analyzed by immunoblotting.

RESULTS

Cerivastatin (10^–9 to 10^–6 mol/liter) enhanced eNOS protein expression and NO release (about two-fold) in EC in response to Ca²⁺ ionophore (10^–6 mol/liter). This was fully abrogated by the HMG-CoA product mevanolate (2 x 10^–4 mol/liter). In SMC, platelet-derived growth factor (5 ng/ml) enhanced ³H-thymidine incorporation (298 ± 23%, n = 4), activated cyclin-dependent kinase (Cdk2), phosphorylated Rb and down-regulated p27^Kip1 (but not p21^Cip1). Cerivastatin reduced the ³H-thymidine incorporation (164 ± 11%, p < 0.01), inhibited Cdk2 activation and Rb phosphorylation, but did not prevent p27^Kip1 down-regulation, nor p42^mapk and p70^S6K activation. Mevalonate abrogated the effects of cerivastatin on Cdk2 and Rb but only partially rescued the ³H-thymidine incorporation (from 164 ± 11% to 211 ± 13%, n = 4, p < 0.01).

CONCLUSIONS

In humans, SVEC inhibition of HMG-CoA/mevalonate pathway contributes to the enhanced eNOS expression and NO release by cerivastatin, whereas in SMC, inhibition of this pathway only partially explains cerivastatin-induced cell growth arrest. Inhibition of mechanisms other than p42^mapk and p70^S6K or Cdk2 are also involved. These effects of cerivastatin could be important in treating venous bypass graft disease.

Abbreviations and Acronyms   Cdks = cyclin-dependent kinases   EC = endothelial cell(s)   eNOS = endothelial nitric oxide synthase   FCS = fetal calf serum   HMG-CoA = 3-hydroxy-3-methylglutaryl CoA   NO = nitric oxide   PBS = phosphate-buffered saline   PDGF = platelet-derived growth factor   SMC = smooth muscle cell(s)   SV = saphenous vein

This article has been cited by other articles:

				T. F. Luscher, M. Pieper, M. Tendera, M. Vrolix, W. Rutsch, F. van den Branden, R. Gil, K.-O. Bischoff, M. Haude, D. Fischer, et al. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study Eur. Heart J., July 1, 2009; 30(13): 1590 - 1597. [Abstract] [Full Text] [PDF]

				K. I. Paraskevas Applications of statins in cardiothoracic surgery: more than just lipid-lowering Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 377 - 390. [Abstract] [Full Text] [PDF]

				A. Kulik, R. Levin, M. Ruel, T. G. Mesana, D. H. Solomon, and N. K. Choudhry Patterns and predictors of statin use after coronary artery bypass graft surgery. J. Thorac. Cardiovasc. Surg., October 1, 2007; 134(4): 932 - 938. [Abstract] [Full Text] [PDF]

				Z. Yang and X.-F. Ming Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin. Med. Res., March 1, 2006; 4(1): 53 - 65. [Abstract] [Full Text] [PDF]

				T. Kozai, M. Eto, Z. Yang, H. Shimokawa, and T. F. Luscher Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway Cardiovasc Res, December 1, 2005; 68(3): 475 - 482. [Abstract] [Full Text] [PDF]

				H. Lorenz, C. Junger, K. Seidl, A. Gitt, S. Schneider, R. Schiele, H. Wienbergen, R. Winkler, M. Gottwik, W. Delius, et al. Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction? Eur. Heart J., June 1, 2005; 26(11): 1078 - 1085. [Abstract] [Full Text] [PDF]

				S Van Doornum, G McColl, and I P Wicks Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis Ann Rheum Dis, December 1, 2004; 63(12): 1571 - 1575. [Abstract] [Full Text] [PDF]

				K. Nakamura, S. Al-Ruzzeh, A. H. Chester, C. Ilsley, M. H. Yacoub, and M. Amrani Differential in vitro response of the human radial artery versus left internal thoracic artery to cerivastatin: implications to bypass grafting Ann. Thorac. Surg., December 1, 2003; 76(6): 2023 - 2028. [Abstract] [Full Text] [PDF]

				J. P. Werba, E. Tremoli, P. Massironi, M. Camera, A. Cannata, F. Alamanni, P. Biglioli, and A. Parolari Statins in coronary bypass surgery: rationale and clinical use Ann. Thorac. Surg., December 1, 2003; 76(6): 2132 - 2140. [Abstract] [Full Text] [PDF]

				P.O Bonetti, L.O Lerman, C Napoli, and A Lerman Statin effects beyond lipid lowering--are they clinically relevant? Eur. Heart J., February 1, 2003; 24(3): 225 - 248. [Full Text] [PDF]

				C. Barandier, X.-F. Ming, and Z. Yang Small G Proteins as Novel Therapeutic Targets in Cardiovascular Medicine Physiology, February 1, 2003; 18(1): 18 - 22. [Abstract] [Full Text] [PDF]

				The ENCORE Investigators* Effect of Nifedipine and Cerivastatin on Coronary Endothelial Function in Patients With Coronary Artery Disease: The ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function) Circulation, January 28, 2003; 107(3): 422 - 428. [Abstract] [Full Text] [PDF]

				K. Nakamura, S. Al-Ruzzeh, A. H. Chester, I. Schmidt, M. Barbir, M. H. Yacoub, and M. Amrani Effects of cerivastatin on vascular function of human radial and left internal thoracic arteries Ann. Thorac. Surg., June 1, 2002; 73(6): 1860 - 1865. [Abstract] [Full Text] [PDF]

				M. Takemoto and J. K. Liao Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1712 - 1719. [Abstract] [Full Text] [PDF]